tldrdailynews.com logo
Tag

Type 2 Diabetes

All articles tagged with #type 2 diabetes

Blood Type B Linked to Modest Increase in Type 2 Diabetes Risk, Study Finds
health14 days ago

Blood Type B Linked to Modest Increase in Type 2 Diabetes Risk, Study Finds

A 2024 umbrella review of 51 meta-analyses (covering about 270 blood-group–health links) finds only one robust association: blood type B has about a 28% higher risk of type 2 diabetes than non-B types; the effect is modest and far smaller than risk factors like diet, obesity, or inactivity, and researchers call for more rigorous work and study of potential mechanisms such as the gut microbiome; published in BMC Medicine.

via ScienceAlert|
#abo-blood-groups#blood-type-b#epidemiology
Lilly's retatrutide delivers strong A1C drops and meaningful weight loss in first Phase 3 Type 2 diabetes trial
health23 days ago

Lilly's retatrutide delivers strong A1C drops and meaningful weight loss in first Phase 3 Type 2 diabetes trial

Lilly reports positive topline results from TRANSCEND-T2D-1, a Phase 3 trial of retatrutide, a once-weekly triple hormone receptor agonist (GIP, GLP-1, glucagon), showing up to a 2.0% reduction in A1C and about 17% body-weight loss at 40 weeks versus placebo, with dose-dependent effects and continued weight loss through the treatment period. The most common side effects were gastrointestinal (nausea, diarrhea, vomiting) largely during dose escalation, with some dysesthesia but generally manageable. Results met primary and key secondary endpoints and will be detailed at the ADA Scientific Sessions in June; Lilly plans to publish additional data from the retatrutide program over the next year.

via Eli Lilly|
#a1c#health#phase-3
Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial
business23 days ago

Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial

Eli Lilly's next‑generation obesity drug retatrutide showed strong Phase 3 results in Type 2 diabetes, lowering A1C by about 1.7%–2% at 40 weeks and achieving roughly 16.8% weight loss at the highest dose among patients who stayed on treatment, with a tolerable safety profile. The company has not filed for approval yet and plans additional Phase 3 trials, pursuing retatrutide as a key pillar of its obesity/diabetes portfolio alongside Zepbound and orforglipron, as Novo Nordisk races to catch up.

via CNBC|
#a1c#business#eli-lilly
GLP-1 Medications Tied to Broad Decrease in Addiction Risk Among Veterans
health1 month ago

GLP-1 Medications Tied to Broad Decrease in Addiction Risk Among Veterans

A VA-led cohort study of 606,434 U.S. veterans with type 2 diabetes found that GLP-1 medicines (including Ozempic, Wegovy, Mounjaro, and Zepbound) are associated with a lower risk of developing substance use disorders across alcohol, opioids, nicotine, cocaine, cannabis and other substances—and with fewer hospitalizations, overdoses, and deaths among veterans who already have an addiction. The study also notes a 25% reduction in suicidal ideation. As observational research, it cannot prove causation, and results may reflect greater health engagement; randomized trials are underway, and GLP-1s are not yet approved as addiction treatments.

via Military.com|
#addiction#cohort-study#glp-1-drugs
Sugary Drinks Linked to 340,000 Deaths Worldwide in 2020
health1 month ago

Sugary Drinks Linked to 340,000 Deaths Worldwide in 2020

A Nature Medicine analysis tying sugar-sweetened beverages to 340,000 deaths in 2020 from heart disease and type 2 diabetes finds 2.2 million new diabetes and 1.2 million heart disease cases linked to SSBs that year. The burden is greatest in Latin America and the Caribbean and sub-Saharan Africa, with younger urban men most affected. Mechanisms include rapid liquid sugar absorption causing glucose spikes, insulin resistance, visceral fat, and inflammation. Experts recommend limiting SSBs and replacing them with water or non-caloric drinks, and suggest less than one serving per week for many people; note that the study is observational, showing association, not causation.

via Prevention|
#health#heart-disease#nutrition
Global Study Reframes Type 2 Diabetes as Tissue-Driven and Population-Specific
science2 months ago

Global Study Reframes Type 2 Diabetes as Tissue-Driven and Population-Specific

A large international genetic study analyzing data from over 2.5 million people across seven tissues finds that many Type 2 diabetes drivers act outside the bloodstream. Only about 18% of causal genes in key diabetes tissues are detectable in blood, while 85% of signals in diabetes-relevant tissues are missed by blood-based analyses. The study links 676 genes to causal effects, including 335 genes and 46 proteins that influence risk, with some associations consistent across ancestry groups and others emerging only in historically underrepresented populations. Published in Nature Metabolism, the work underscores the importance of tissue context and population diversity for improving prevention and treatment strategies.

via SciTechDaily|
#blood-based-analyses#genetics#global-populations
Bariatric Surgery Surpasses GLP-1 Meds for Diabetes Across Socioeconomic Lines
health2 months ago

Bariatric Surgery Surpasses GLP-1 Meds for Diabetes Across Socioeconomic Lines

A secondary analysis of a large randomized trial found bariatric surgery produced stronger diabetes control and greater weight loss (about 28% vs 10%) than medical therapy across social backgrounds, though the rapid rise of obesity drugs and study limitations temper interpretation; overall, surgery remains underutilized and should remain a discussion option for patients.

via statnews.com|
#bariatric-surgery#glp-1#health